Highlands Oncology Group

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

José Baselga, Mario Campone, Martine Piccart et al. · New England Journal of Medicine · 2011 · 2.8K citations · Full text

Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer

Dennis J. Slamon, Patrick Neven, Stephen Chia et al. · New England Journal of Medicine · 2019 · 797 citations · Full text

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

Paolo A. Ascierto, Dirk Schadendorf, Carola Berking et al. · The Lancet Oncology · 2013 · 638 citations

Tumor Biology, Open-label Phase 2, Medicine +12

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years

Paul E. Goss, James N. Ingle, Kathleen I. Pritchard et al. · New England Journal of Medicine · 2016 · 633 citations · Full text

Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer

Mary L. Disis, Matthew H. Taylor, Karen Kelly et al. · JAMA Oncology · 2019 · 417 citations · Full text